Zacks Investment Research
29 May 2026, 15:51 UTC · 3h ago
Source · https://www.zacks.com/stock/news/2929121/lly-stock-gains-4-to-all-time-high-is-obesity-access-the-catalyst?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2929121
Read source
Search tags
Story key points
4 claims · impact-rated
All three of the largest U.S. pharmacy benefit managers (PBMs) now cover Eli Lilly's obesity medicine portfolio. — Broad insurance coverage is a primary driver of prescription volume and revenue growth for high-cost blockbuster drugs.
+0.80CVS Caremark will cover Lilly's oral GLP-1 pill, Foundayo, starting June 1, 2026, and resume broader coverage of Zepbound by October 1, 2026. — Regaining access to the CVS network removes a significant barrier to patient acquisition and sales growth.
+0.60Eligible commercially insured patients may pay as little as $25 per month for Lilly's obesity therapies under the new coverage terms. — Lower out-of-pocket costs typically increase patient adherence and adoption rates.
+0.40Continue reading
6 related stories
Novo Nordisk maintains a first-mover advantage in the oral obesity market, having launched its oral Wegovy in January 2026. — First-mover advantage in a high-growth category can create long-term competitive headwinds for followers like Lilly.
Ticker attribution
Model heads
Shares hit a record high following an expansion of insurance coverage for its obesity portfolio by major PBMs.
Maintains a first-mover advantage in oral obesity medication and had preferred status with CVS, though facing increased competition from Lilly.
Mentioned as a provider of pharmacy benefit management services without a specific impact on its own stock performance.
[mutual] Novo Nordisk is identified as Eli Lilly's primary rival in the obesity treatment market.
[a_to_b] CVS Caremark is a pharmacy benefit manager providing insurance coverage for Eli Lilly's obesity medications.
[a_to_b] CVS provides insurance coverage for Novo Nordisk's Wegovy and designated it as a preferred therapy.
Impact vectors
8 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Reuters
2h ago
